OncoSec’s Novel COVID-19 Vaccine Candidate

OncoSec Medical Incorporated , a company developing late-stage intratumoral DNA–based cancer immunotherapies, announced on July 13th the promising potential of its novel DNA–encodable vaccine candidate, CORVax12, which is designed to act as a prophylactic vaccine to prevent COVID-19, was featured in the show ‘Straight Talk’ by KGW NewsChannel 8, an NBC TV affiliate in Portland, Oregon . OncoSec and researchers at Providence Cancer Institute previously announced a collaboration to conduct a first-in-human trial of OncoSec’s CORVax12 vaccine candidate.  Providence has filed an Investigator-Initiated Investigational New Drug (IND) Application with the United States Food and Drug Administration (FDA) and plans to initiate a phase 1 vaccine trial of healthy adult volunteers upon FDA clearance. CORVax12 consists of OncoSec’s existing product candidate, TAVO™ (interleukin-12 or “IL-12” plasmid), in combination with an immunogenic component of the SARS-CoV-2 virus recently developed by researchers at NIH’s National Institute of Allergy and Infectious Diseases (“NIAID”) and licensed to OncoSec on a non-exclusive basis.  Specifically, OncoSec’s CORVax12 vaccine approach combines the co-administration of TAVO with a DNA-encodable version of the SARS-CoV-2 spike or “S” glycoprotein to enhance immunogenicity of the component developed by scientists at the NIAID Vaccine Research Center.  CORVax12 is designed to drive a coordinated vaccine response, capable of drawing upon the innate, adaptive humoral, and adaptive cellular arms.  Researchers believe this multi-pronged innate, adaptive and cellular immune response is likely to be important in generating a robust anti-viral response.

For further information, see OncoSec (https://ir.oncosec.com/press-releases/detail/2055/oncosecs-novel-covid-19-vaccine-candidate-featured-in)

Leave a Reply

Your email address will not be published. Required fields are marked *